Western Australian biotechnology company pSivida has led the charge of Australia’s small to medium-cap stocks, which, as a group, rose 40 per cent in the year to June.
pSivida rose 107 per cent with its progress in developing biosilicon for drug delivery and diagnostic applications, according to the Intersuisse Small Cap 150 Index.
Unfortunately WA also featured at the negative end of that scale as well.
While most of the companies on the 150 rose (96), another 63 recorded falls and Clough Limited had one of the greatest. It fell 41 per cent in the six months to June.